These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 10953328)
1. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line. Pu QQ; Bezwoda WR Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328 [TBL] [Abstract][Full Text] [Related]
2. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL). Pu Q; Bianchi P; Bezwoda WR Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327 [TBL] [Abstract][Full Text] [Related]
3. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Pu QQ; Bezwoda WR Mol Pharmacol; 1999 Jul; 56(1):147-53. PubMed ID: 10385695 [TBL] [Abstract][Full Text] [Related]
4. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971 [TBL] [Abstract][Full Text] [Related]
5. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Emmons M; Boulware D; Sullivan DM; Hazlehurst LA Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798 [TBL] [Abstract][Full Text] [Related]
7. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Deffie AM; Batra JK; Goldenberg GJ Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693 [TBL] [Abstract][Full Text] [Related]
8. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Barret JM; Calsou P; Larsen AK; Salles B Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322 [TBL] [Abstract][Full Text] [Related]
9. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060 [TBL] [Abstract][Full Text] [Related]
11. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198 [TBL] [Abstract][Full Text] [Related]
12. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Robson CN; Hoban PR; Harris AL; Hickson ID Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220 [TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Eder JP; Chan VT; Ng SW; Rizvi NA; Zacharoulis S; Teicher BA; Schnipper LE Cancer Res; 1995 Dec; 55(24):6109-16. PubMed ID: 8521401 [TBL] [Abstract][Full Text] [Related]
14. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL. Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413 [TBL] [Abstract][Full Text] [Related]
16. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045 [TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16. Hong JH Hiroshima J Med Sci; 1989 Dec; 38(4):197-207. PubMed ID: 2561562 [TBL] [Abstract][Full Text] [Related]
18. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343 [TBL] [Abstract][Full Text] [Related]
19. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719 [TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]